At least 21 biotechs and pharmas are slated to report earnings this week. Both Shire plc (LSE:SHP; NASDAQ:SHGP) and United Therapeutics Corp. (NASDAQ:UTHR) are expected to report 1Q14 EPS growth of more than 25% on strong top-line growth. Revenues for biopharma Shire are expected to grow by 19% to $1.4 billion, while cardiopulmonary company United Therapeutics is expected to post a 22% jump in revenues to $300 million.

1Q14 loss per share for Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is expected to narrow, despite a 59% decline in revenues to $133.8 million. The large-cap biotech has been cutting HCV-related SG&A as sales